Buscar
Mostrando ítems 1-10 de 65
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
(Oxford University Press, 2022)
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
(Oxford University Press, 2023)
Costo-efectividad de Apixaban frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer
Introduction: The incidence rate of venous thromboembolism in cancer patients is 5.8 per 100 years / person. The mainstay of treatment is LMWH, which is associated with poor adherence due to the type of administration. ...
Eficacia del apixaban versus dalteparina como tratamiento de la tromboembolia venosa asociada al cáncer: revisión sistemática
(Universidad Científica del SurPE, 2024)
Antecedentes y objetivos El tromboembolismo venoso (TEV) es común en pacientes con cáncer. La terapia anticoagulante con heparinas de bajo peso molecular (HBPM) y los anticoagulantes orales directos (ACOD), como dalteparina ...
Revisión de los ensayos clínicos de anticoagulantes orales y antiagregantes en fibrilación auricular
(Sociedad Uruguaya de Cardiología, 2012)
EDITORIAL Desde el apixaban hasta la aspirina, en la prevención del tromboembolismo venoso recurrente.
(Universidad del Zulia, 2013)
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis
(Elsevier B.V., 2015-03-09)
Objective To systematically review the literature and to quantitatively evaluate the efficacy and safety of extended pharmacologic treatment of venous thromboembolism (VTE) through network meta-analysis (NMA). Methods A ...
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patients undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial
(2020-09-01)
Background: New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective ...